Myriad Genetics Inc.

(MYGN) Trade

By |

Profile

Myriad Genetics is a molecular diagnostics company, which provides testing services designed to assess an individual's risk of developing a disease. The firm produces myRisk, a 28-gene panel with the capability to identify the elevated risk of developing 8 types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Vectra DA, which predicts disease progression in rheumatoid arthritis to optimize drug treatment; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.

Contact Information

Website: www.myriad.com
Email: sgleason@myriad.com
Main Phone: +1 801 584-3600
Address: 320 Wakara Way
State: UT
City / Town: Salt Lake City
Country: US
Postal Code: 84108

Issuer Information

Exchange: NGS
CEO: Paul J. Diaz
Employees: 2700
NAICS: In-Vitro Diagnostic Substance Manufacturing(325413)

Equities News

View More

Profile

Myriad Genetics is a molecular diagnostics company, which provides testing services designed to assess an individual's risk of developing a disease. The firm produces myRisk, a 28-gene panel with the capability to identify the elevated risk of developing 8 types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Vectra DA, which predicts disease progression in rheumatoid arthritis to optimize drug treatment; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.

Contact Information

Website: www.myriad.com
Email: sgleason@myriad.com
Main Phone: +1 801 584-3600
Address: 320 Wakara Way
State: UT
City / Town: Salt Lake City
Country: US
Postal Code: 84108

Issuer Information

Exchange: NGS
CEO: Paul J. Diaz
Employees: 2700
NAICS: In-Vitro Diagnostic Substance Manufacturing(325413)

Equities News

View More
$ 12.93 $ 0.39 (3.11%)
Last Price 12.93 Change $ 0.39 Change % 3.11 Tick N/A
Bid 11.81 Bid Size 100.00 Ask 12.92 Ask Size 500.00
Open 12.69 High 13.00 Low 12.35 Prev Close 12.54
Last Trade Volume 2.4 mi 52 Wk Hi 35.30 52 Wk Low 9.24
Market Cap 966 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 74,709,313.00 EPS (TTM) -2.69 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 20 84
Number of Buys 10 34
Number of Sells 10 50
Net Activity 0 393354
Last 10 Buys Shares
John T. Henderson 1,000
John T. Henderson 1,000
John T. Henderson 1,000
Mark Christopher Capone 1,000
Ralph L. Mcdade 1,000
John T. Henderson 1,000
Last 10 Sell Shares
Dennis H. Langer 1,000
Dennis H. Langer 1,000
Walter Gilbert 1,000
Dennis H. Langer 1,000
Dennis H. Langer 1,000
Walter Gilbert 1,000
Dennis H. Langer 1,000
Dennis H. Langer 1,000
Dennis H. Langer 1,000
Dennis H. Langer 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 45 45 45 45
Low Target Price Estimate 20 20 20 20
Mean Target Price Estimate 34 34 34 34
Standard Deviation 7.13 7.13 7.13 7.13
Date of Most Recent Estimate 06/04/18 05/14/18 05/14/18 06/04/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 3 3 3 3
Moderate Buy 0 0 0 0
Hold 7 7 8 8
Moderate Sell 1 1 1 1
Strong Sell 1 1 1 2
Mean Rec. 2.75 2.75 2.77 2.88